The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review

References

• Gérard JP, Barbet N, Gal J, et al. Planned organ preservation for early T2-3 rectal adenocarcinoma: a French, multicentre study. Eur J Cancer. 2019;108:1–16.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–927.
   PubMed Web of Science ®Google Scholar
• Benezery K, Montagne L, Evesque L, et al. Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: the time/dose factor influence. Clin Transl Radiat Oncol. 2020;24:92–98.
   PubMed Web of Science ®Google Scholar
• Jankowski M, Pietrzak L, Rupiński M, Polish Colorectal Study Group, et al. Watch-and-wait strategy in rectal cancer: is there a tumour size limit? Results from two pooled prospective studies. Radiother Oncol. 2021;160:229–235.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88(4):822–828.
   PubMed Web of Science ®Google Scholar
• Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: Can We detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum. 2016;59(4):255–263.
   PubMed Web of Science ®Google Scholar
• Garant A, Magnan S, Devic S, et al. Image guided adaptive endorectal brachytherapy in the nonoperative management of patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2019;105(5):1005–1011.
   PubMed Web of Science ®Google Scholar
• Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol. 2015;115(2):246–252.
   PubMed Web of Science ®Google Scholar
• Rijkmans EC, Marijnen CAM, van Triest B, et al. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiother Oncol. 2019;133:176–182.
   PubMed Web of Science ®Google Scholar
• van der Valk MJM, Hilling DE, Bastiaannet E, IWWD Consortium, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the international watch & wait database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–2545.
   PubMed Web of Science ®Google Scholar
• Chin RI, Roy A, Pedersen KS, et al. Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and nonoperative management. Int J Radiat Oncol Biol Phys. 2022;112(3):715–725.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–2556.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, São Julião GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!. Dis Colon Rectum. 2019;62(7):802–808.
   PubMed Web of Science ®Google Scholar
• Smith FM, Wiland H, Mace A, et al. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57(3):311–315.
   PubMed Web of Science ®Google Scholar
• Yuval JB, Verheij FS, Lin ST, On behalf of the OPRA consortium, et al. Clinical and radiological predictors of organ preservation in patients with rectal cancer treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(16_suppl):3619–3619.
   Web of Science ®Google Scholar
• Jimenez-Rodriguez RM, Quezada-Diaz F, Hameed I, et al. Organ preservation in patients with rectal cancer treated with total neoadjuvant therapy. Dis Colon Rectum. 2021;64(12):1463–1470.
   PubMed Web of Science ®Google Scholar
• Mbanu P, Osorio EV, Mistry H, et al. Clinico-pathological predictors of clinical complete response in rectal cancer. Cancer Treat Res Commun. 2022;31:100540.
   PubMedGoogle Scholar
• Gerard J-P, Barbet NN, Pacé-Loscos T, et al. Contact x-ray brachytherapy (papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: the 3-year results of OPERA randomized trial (NCT02505750). J Clin Oncol. 2022;40(16_suppl):3512–3512.
   Web of Science ®Google Scholar
• Lutsyk M, Awawda M, Gourevich K, et al. Tumor volume as predictor of pathologic complete response following neoadjuvant chemoradiation in locally advanced rectal cancer. Am J Clin Oncol. 2021;44(9):482–486.
   PubMed Web of Science ®Google Scholar
• Martens MH, van Heeswijk MM, van den Broek JJ, et al. Prospective, multicenter validation study of magnetic resonance volumetry for response assessment after preoperative chemoradiation in rectal cancer: can the results in the literature be reproduced? Int J Radiat Oncol Biol Phys. 2015;93(5):1005–1014.
   PubMed Web of Science ®Google Scholar
• Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47(2):167–174.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Leon O, Gunnlaugsson A, et al. Determinants for local tumour control probability after radiotherapy of anal cancer. Radiother Oncol. 2018;128(2):380–386.
   PubMed Web of Science ®Google Scholar
• Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 european society of gastrointestinal and abdominal radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(4):1465–1475.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R. Watch and wait in rectal cancer: is it time to subclassify cT3? Lancet Gastroenterol Hepatol. 2018;3(12):814–815.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, São Julião GP, Vailati BB, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269(1):102–107.
   PubMed Web of Science ®Google Scholar
• São Julião GP, Habr-Gama A, Vailati BB, et al. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer? Eur J Surg Oncol. 2018;44(1):93–99.
   PubMed Web of Science ®Google Scholar
• Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825–836.
   PubMed Web of Science ®Google Scholar